Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

TD Ameritrade Institutional Supports Bills That Benefit Individual Investors, Small Businesses and Independent RIAs

Published

on

Reading Time: 4 minutes

As SEC Readies for Vote on Regulation BI, RIA Advocate Skip Schweiss
Heads to Capitol Hill to Meet Policymakers

JERSEY CITY, N.J.–(BUSINESS WIRE)–$AMTD #Advocating4you–Investing for retirement has never been more critical, but some current
policies create roadblocks for investors, small businesses, and the
independent registered investment advisors (RIAs) who guide them. As
Congress considers legislation to help address the nation’s retirement
savings crisis, TD
Ameritrade Institutional
1 reiterates its support for
proposals that help investors plan and save for their long-term
financial goals.

Skip Schweiss, Managing Director of Advisor Advocacy and Industry
Affairs for TD Ameritrade Institutional, is meeting with members of
Congress and their staffs in Washington this week and next to raise
awareness on a range of issues impacting investors and independent RIAs.
On June 5 and 6, Schweiss will join other Financial
Planning Association
members and industry leaders on Capitol Hill.
On June 13, he’ll take to the Hill again as a participant in the Investment
Adviser Association
’s Advocacy Day. TD Ameritrade Institutional is a
sponsor of both of these events.

Tax reform, SEC regulation and advisor oversight, investor protections,
small business access to retirement plans, restoration of the investor
deduction for advisory fees, extension of the pass-through deduction for
RIA firms, and cybersecurity are just a few of the items that will be
discussed.

“TD Ameritrade Institutional for 15 years has proudly stood and fought
at the side of RIAs. We come to Washington to help make their voices
heard on policies and rules that can impact their clients and their
firms,” said Schweiss. “Investing for their retirement, for one, is
critical for American families and for our country as a whole. We should
make it easier, not more difficult, for investors to pursue their
financial goals.”

The U.S.
Government Accountability Office
recently reported that roughly half
(48%) of households headed by someone 55 years of age or older have no
retirement savings.2 And earlier this year, the National
Institute on Retirement Security
found that the typical retirement
account balance is $40,000.3

Schweiss goes to Washington just as Congress takes up two bills related
to retirement savings: the Retirement Enhancement and Savings Act of
2019 (RESA), in the Senate, and the Setting Every Community Up for
Retirement Enhancement (SECURE) Act of 2019, which passed in the House
of Representatives on May 23. Both bills would, among other things,
raise the required minimum distribution age from 70½ to 72, enable small
businesses to work together to form multi-employer 401(k) plans and make
part-time workers eligible for retirement benefits.

Reg BI Up for SEC Vote on June 5

RIAs are meeting lawmakers at a historic moment.

On June 5, the SEC Commissioners are set to vote on one of the most
significant proposed regulatory changes in decades: Regulation Best
Interest (Reg BI) 4, proposed in April 2018, which would
establish new standards for brokers making investment recommendations as
part of a package of new rules to be applied to brokers and investment
advisors.

Also on June 5, the SEC Commissioners will vote on whether to publish an
interpretation of the “solely Incidental” language found in the
Investment Advisers Act of 1940. This interpretation was not part of the
April 2018 proposals.

Advisors have mixed views of the proposed regulation. A recent survey of
independent RIAs5 conducted for TD Ameritrade Institutional
found that though half (51%) say they do not have strong opinions on the
SEC’s Reg BI as proposed, 35 percent say they are in favor of it, while
14 percent are opposed. But if Reg BI as proposed were enacted, roughly
half (48%) of RIAs expect business will continue as usual.

RIAs accept some aspects of the SEC’s proposed Reg BI but are lukewarm
on others. More than seven in 10 agree with introducing licensing and
continuing education requirements for RIAs, and 85 percent believe RIA
clients should receive periodic statements showing fees. On the other
hand, 45 percent disagree with imposing minimum capital requirements on
RIA firms, and 69 percent oppose RIA fidelity bonding requirements.

“Regulations can impact the ability of thousands of independent advisors
to compete in the marketplace, yet most RIA firms are small businesses
that need to focus on serving their clients,” said Schweiss. “We come to
Washington to amplify their voices and look out for their interests. We
also continue to tell policymakers that investors are better served by
rules that offer strong protections in the financial markets and
increase access to independent investment advice.”

The survey conducted for TD Ameritrade Institutional also found that
independent RIAs consider regulatory issues to be their top management
challenge. Advisors also say that, second only to technology, their
biggest spending increases year after year are on managing regulatory
and legal issues.

To learn more about TD Ameritrade Institutional’s RIA advocacy efforts,
please visit https://www.tdainstitutional.com/why-ria/advocacy.html

About TD Ameritrade Holding Corporation

TD Ameritrade provides investing
services
 and education to
more than 11 million client accounts totaling approximately $1.3
trillion in assets, and custodial
services
 to more than 7,000 registered investment advisors. We are a
leader in U.S. retail trading, executing an average of approximately
850,000 trades per day for our clients, more than a quarter of which
come from mobile devices. We have a proud history
of innovation
, dating back to our start in 1975, and today our team
of 10,000-strong is committed to carrying it forward. Together, we are
leveraging the latest in cutting edge technologies and one-on-one client
care to transform lives, and investing, for the better. Learn more by
visiting TD Ameritrade’s newsroom at www.amtd.com,
or read our stories at Fresh
Accounts
.

About TD Ameritrade Institutional

TD
Ameritrade Institutional
empowers more than 7,000 independent
registered investment advisors to transform the lives of their clients.
It provides powerful technology and resources that help simplify running
a business and let advisors spend more time doing what matters most —
serving their clients. Through meaningful innovation, steadfast advocacy
and unwavering service, TD Ameritrade Institutional supports RIAs as
they build businesses that positively impact their clients and
communities. TD Ameritrade Institutional is a division of TD Ameritrade,
Inc., member FINRA/SIPC, a brokerage subsidiary of TD Ameritrade Holding
Corp.

Brokerage services provided by TD Ameritrade, Inc., member FINRA (www.FINRA.org)
/ SIPC (www.SIPC.org).

1 TD Ameritrade Institutional is a division of TD Ameritrade,
Inc., a brokerage subsidiary of TD Ameritrade Holding Corporation
2
Retirement
Security: Most Households Approaching Retirement Have Low Savings
,
U.S. Government Accountability Office, March 26, 2019
3 Retirement
Insecurity 2019
, National Institute on Retirement Security, March
2019
4 SEC
Open Meeting Agenda
, Wednesday, June 5, 2019, Securities and
Exchange Commission
5 2019
RIA Sentiment Survey
, TD Ameritrade Institutional, January 2019

Source: TD Ameritrade Holding Corporation

Contacts

Media Contact:
Joseph A.
Giannone
Communications + Public Affairs
T: 201-369-8705
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand

Published

on

Continue Reading

transfer

IMC to transfer its Oranim Pharmacy shares back to the seller

Published

on

imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller

TORONTO and GLIL YAM, Israel, April 16, 2024 /PRNewswire/ — IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the “Company” or “IMC“), a leading medical cannabis company with operations in Israel and Germany, is announcing that, further to the news release dated January 12, 2024, the Company has decided not to make remaining installment payments installments (i.e. NIS 5,873K including interest or 2,154K CAD) by IMC Holdings Ltd., and as such will transfer the 51% shares held by IMC Holdings Ltd back to the  seller.

“With the April 1st cannabis legalization in Germany, we are focusing our resources on the German market, where we expect to see the biggest growth potential,” said Oren Shuster, CEO of IMC. “With both of our core markets, Germany and Israel, currently undergoing rapid evolution, we need to assure that we allocate our resources to the growth opportunities where we expect the best return on investment.”

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC’s products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis at its own facilities under the WAGNERS and Highland Grow brands for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to,  the occurrence of growth opportunities and the likelihood of growth potential.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the development and introduction of new products; continuing demand for medical and adult-use recreational cannabis in the markets in which the Company operates; the Company’s ability to reach patients through both e-commerce and brick and mortar retail operations; the Company’s ability to maintain and renew or obtain required licenses; the effectiveness of its products for medical cannabis patients and recreational consumers; and the Company’s ability to market its brands and services successfully to its anticipated customers and medical cannabis patients.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward looking statements due to a number of factors and risks. These include: any failure of the Company to maintain “de facto” control over Focus Medical in accordance with IFRS 10; the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the effect of the reform on the Company; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the “Group”) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East

Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made.

The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contacts:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
[email protected]

Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller-302117984.html

Continue Reading

Cannabis

Right on Brands Announces Major Product Line Expansion via HONEY® Brands

Published

on

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania